BEAT-HF: No Benefit to Mirabegron on LVEF in Chronic HF Patients
The β3-adrenoceptor agonist Mirabegron did not increase left ventricular ejection fraction (LVEF) in patients with chronic heart failure (HF), according to results from the BEAT-HF trial presented Nov. 11 during AHA 2015 in Orlando.
The first-in-man trial randomized 70 patients to either 300 mg of Mirabegron daily, or placebo for six months. Results showed that Mirabegron did not increase LVEF in patients with a mean ejection fraction of 40 percent. However, the investigators note that an "exploratory analysis indicated an increase in LVEF in patients with more severe HF at baseline, but not in patients with EF ≥ 40 percent."
The investigators conclude that moving forward, "an additional study on effects of β3-adrenoceptor agonists in patients with severe HF is needed for the design of a phase III trial."
< Back to Listings